Steven Park to Lymphoma, Large B-Cell, Diffuse
This is a "connection" page, showing publications Steven Park has written about Lymphoma, Large B-Cell, Diffuse.
Connection Strength
1.976
-
Moore DC, Soni AC, Hu B, Smith ET, Levine J, Moyo TK, Jacobs R, Ghosh N, Park SI. Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Br J Haematol. 2022 Feb; 196(4):e30-e33.
Score: 0.787
-
Hill H, Arnall J, Janes A, Hatley C, Swift K, Hargett C, Howell T, Griffin S, Larck C, Park S. A review of R-DHAP administration in the outpatient setting and a case of the alternative regimen R-DHAX given outpatient for refractory diffuse large B-cell lymphoma. J Oncol Pharm Pract. 2019 Dec; 25(8):2041-2044.
Score: 0.650
-
Hu B, Boselli D, Pye LM, Chen T, Bose R, Symanowski JT, Blackley K, Moyo TK, Jacobs R, Park SI, Soni A, Avalos BR, Copelan EA, Raghavan D, Ghosh N. Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphoma. Cancer. 2021 Nov 01; 127(21):3991-3997.
Score: 0.194
-
Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Miller TP, Friedberg JW. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol. 2020 Sep 10; 38(26):3003-3011.
Score: 0.180
-
Ghosh N, Sanikommu S, Robinson M, Trivedi J, Brown T, Bose R, Park SI, Avalos BR, Copelan EA, Jacobs R, Hu B. Curative potential of chemoimmunotherapy in diffuse large B cell lymphoma with hepatic and/or renal dysfunction. Br J Haematol. 2019 Aug; 186(4):e65-e67.
Score: 0.165